REG - Agronomics Limited - Exercise of Warrants

AgronomicsAnnouncement

10/01/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220110:nRSJ9132Xa&default-theme=true

RNS Number : 9132X  Agronomics Limited  10 January 2022

10 January 2022

Agronomics Limited

("Agronomics" or the "Company")

Exercise of Warrants

Agronomics Limited (AIM:ANIC), a leading listed company focused on cellular
agriculture, announces that pursuant to the receipt of notice for the exercise
of warrants, it is issuing 5,872 new Ordinary Shares with a nominal value of
£0.000001 each in the capital of the Company ("Shares") at a subscription
price of 30.0p per Share, and 567,012 new Shares at a subscription price of
28.5p per Share. The Company has received gross proceeds of £163,360.

Application has been made for the 572,884 new Shares to be admitted to trading
on AIM ("Admission"), with Admission expected to occur on or around 14 January
2022.

The new Shares will rank pari passu with the existing Shares, including the
right to receive all dividends and other distributions declared after the date
of their issue.

Following Admission of the new Shares, the Company will have 938,590,207
ordinary shares with a nominal value of £0.000001 each in issue with voting
rights and admitted to trading on AIM. This figure may then be used by
shareholders in the Company as the denominator for the calculation by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under the
Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please contact:

 

 Agronomics           Beaumont              Cenkos                Peterhouse Capital

 Limited              Cornish Limited       Securities Plc        Limited               TB Cardew
 The Company          Nomad                 Joint Broker          Joint Broker          Public Relations
 Richard Reed         Roland Cornish        Giles Balleny         Lucy Williams         Ed Orlebar

 Denham Eke           James Biddle          Michael Johnson       Charles Goodfellow    Joe McGregor
 +44 (0) 1624 639396  +44 (0) 207 628 3396  +44 (0) 207 397 8900  +44 (0) 207 469 0936  +44 (0) 20 7930 0777

 info@agronomics.im                                                                     +44 (0) 7738 724 630

                                                                                        agronomics@tbcardew.com

 

 

About Agronomics (https://agronomics.im/)

Agronomics is a leading listed alternative proteins company with a focus on
cellular agriculture and cultivated meat. The Company has established a
portfolio of 16 companies at the Seed to Series B stage in this rapidly
advancing sector. It seeks to secure minority stakes in companies owning
technologies with defensible intellectual property that offer new ways of
producing food and materials with a focus on products historically derived
from animals. These technologies are driving a major disruption in
agriculture, offering solutions to improve sustainability, as well as
addressing human health, animal welfare and environmental damage. This
disruption will decouple supply chains from the environment and animals, as
well as being fundamental to feeding the world's expanding population. A full
list of Agronomics' portfolio companies is available at https://agronomics.im/
(https://agronomics.im/) .

 

About the Cultivated Meat Sector

Funding in the cultivated meat sector is growing rapidly with approximately
US$ 170 million invested worldwide between 2016-2019 and over US$ 270 million
raised in 2020 alone. Additional financings are anticipated as the capital
requirements of these companies grows to build out and scale up manufacturing
facilities.  Currently it is estimated that there are 60 companies globally
within the sector. AT Kearney, a global consultancy, has predicted that
Cultivated Meat's market share of meat consumption will be 35% by 2040.

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 ('MAR'). Upon the publication of this announcement via a
Regulatory Information Service ('RIS'), this inside information is now
considered to be in the public domain.

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEAPFEFENAEEA